Metagenomics of the gut microbiome of individuals treated with ReFerm

A 24 weeks prospective, randomised controlled clinical trial aiming to investigate if a postbiotic drink made of fermented oats, ReFerm, could alter the progression of liver disease compared to an active comparator, Fresubin. From March 2019 to January 2021, 56 patients were recruited and included in the study. Patients were allocated in a 1:1 ratio to either ReFerm or Fresubin treatment groups. Clinical investigations were conducted at baseline, 4 weeks, 24 weeks (end of intervention), and after a wash-out period of 6 to 8 weeks.